Sai Parenterals acquires 60% of Prathyak Laboratories for Rs. 15 crore
As filed · Sai Parenterals Limited has informed the Exchange regarding a press release dated October 05, 2026, titled "Sai Parenterals Completes the Acquisition of R&D Facility Prathyak Laboratories".
What happened
FactSai Parenterals has completed the acquisition of a 60% equity stake in Prathyak Laboratories Private Limited for Rs. 15 crore, funded by unutilised IPO proceeds. The operating R&D centre, now renamed Sai Prathyak Laboratories Private Limited, becomes a direct subsidiary and brings 28 research scientists plus a development pipeline of 150 SKUs across 86 molecules.
Why it matters
CapitSignal interpretationAn acquisition spends cash or issues shares today for earnings that arrive later, so the price paid and the funding route decide whether holders gain.
Scale
- 9.2% of FY26 revenue
₹15 Cr stated in the filing against ₹162.25 Cr revenue (FY26, standalone)
Source: financial_facts · exchange_table
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
RevisedQ4FY26 revenue stood at X197.93 crores with growth of 166.65% on Q-o-Q basis; EBITDA stood at X28.97 crores with growth of 366.97% on Q-o-Q basis; PAT stood at X13.25 crores with growth of 736.04% on Q-o-Q basis;
FY26 revenue stood at X380.99 crores with growth of 140.37% on Y-o-Y basis; EBITDA stood at X47.21 crores with growth of 33.29% on Y-o-Y basis; and PAT stood at X14.37 crores with growth of 45.52% on Y-o-Y basis
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Consideration and how it is funded
- Revenue and profit of the target
- Expected completion date
- With ongoing capex of ~%440 crores expected to be completed in FY27, we believe the company is well positioned (management committed by FY27)
- The Construction of Australia’s largest and most modern pharmaceutical plant built with Capex of AUD 53 millio (management committed by Q4FY27)
Evidence
- Sai Parenterals Limited has informed the Exchange regarding a press release dated October 05, 2026, titled "Sai Parenterals Completes the Acquisition of R&D Facility Prathyak Laboratories".(opens the original filing in a new tab)
- Earlier statement · Q4 FY26
- Latest statement · Q4 FY26
- Earlier statement · Q4 FY26
How CapitSignal classified this
- Reasoning:
- The purchase replaces a planned greenfield R&D centre, allowing the company to begin development work immediately rather than building a facility and assembling a team. The R&D platform is intended to support complex injectable and oncology products, expanded injectable production, and new-product commitments under Australian and New Zealand supply agreements.
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%